REVOLADE 25 mg, powder for oral suspension 30 sachets
Active ingredients: Eltrombopag, Eltrombopag olamine
Commercialized according to BDPMDispensing in France: Prescription only
Powder for oral suspension30 sachetsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- REVOLADE 25 mg, poudre pour suspension buvable
- Pharmaceutical form
- poudre pour suspension buvable
- Route of administration
- orale
- Presentation description
- 30 sachet(s) polytéréphtalate (PET) OPA : polyamide orienté aluminium polyéthylène basse densité (PEBD) dans kits d'administration avec flacons de mélange en PEHD + seringues pour administration orale + bouchons à vis avec embout adaptateur pour seringue
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Sept 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67675236CIP73006106CIP133400930061060Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ELTROMBOPAG OLAMINEpoudre | — | SA |
| ELTROMBOPAGpoudre | 25 mg · un sachet | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.